Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid
Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disea...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Saad, Fred [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise - Feng, Jing ELSEVIER, 2018, official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:65 ; year:2014 ; number:1 ; pages:146-153 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.eururo.2012.05.007 |
|---|
| Katalog-ID: |
ELV017491231 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV017491231 | ||
| 003 | DE-627 | ||
| 005 | 20230623135051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eururo.2012.05.007 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014010000014.pica |
| 035 | |a (DE-627)ELV017491231 | ||
| 035 | |a (ELSEVIER)S0302-2838(12)00541-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 500 |q VZ |
| 084 | |a 33.25 |2 bkl | ||
| 084 | |a 31.00 |2 bkl | ||
| 100 | 1 | |a Saad, Fred |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid |
| 264 | 1 | |c 2014 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. | ||
| 650 | 7 | |a Castration-resistant prostate cancer |2 Elsevier | |
| 650 | 7 | |a Bone metastasis |2 Elsevier | |
| 650 | 7 | |a Prostate-specific antigen |2 Elsevier | |
| 650 | 7 | |a Skeletal complications |2 Elsevier | |
| 650 | 7 | |a Zoledronic acid |2 Elsevier | |
| 650 | 7 | |a Bisphosphonates |2 Elsevier | |
| 650 | 7 | |a PSA kinetics |2 Elsevier | |
| 700 | 1 | |a Segal, Scott |4 oth | |
| 700 | 1 | |a Eastham, James |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Feng, Jing ELSEVIER |t Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |d 2018 |d official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology |g Amsterdam [u.a.] |w (DE-627)ELV000464341 |
| 773 | 1 | 8 | |g volume:65 |g year:2014 |g number:1 |g pages:146-153 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.eururo.2012.05.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 33.25 |j Thermodynamik |j statistische Physik |q VZ |
| 936 | b | k | |a 31.00 |j Mathematik: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 65 |j 2014 |e 1 |h 146-153 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
f s fs |
|---|---|
| matchkey_str |
saadfredsegalscotteasthamjames:2014----:rsaepcfcniekntcaducmsnainsihoeeatssrmataineitnpottcn |
| hierarchy_sort_str |
2014 |
| bklnumber |
33.25 31.00 |
| publishDate |
2014 |
| allfields |
10.1016/j.eururo.2012.05.007 doi GBVA2014010000014.pica (DE-627)ELV017491231 (ELSEVIER)S0302-2838(12)00541-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics Elsevier Segal, Scott oth Eastham, James oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:65 year:2014 number:1 pages:146-153 extent:8 https://doi.org/10.1016/j.eururo.2012.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 65 2014 1 146-153 8 045F 610 |
| spelling |
10.1016/j.eururo.2012.05.007 doi GBVA2014010000014.pica (DE-627)ELV017491231 (ELSEVIER)S0302-2838(12)00541-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics Elsevier Segal, Scott oth Eastham, James oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:65 year:2014 number:1 pages:146-153 extent:8 https://doi.org/10.1016/j.eururo.2012.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 65 2014 1 146-153 8 045F 610 |
| allfields_unstemmed |
10.1016/j.eururo.2012.05.007 doi GBVA2014010000014.pica (DE-627)ELV017491231 (ELSEVIER)S0302-2838(12)00541-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics Elsevier Segal, Scott oth Eastham, James oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:65 year:2014 number:1 pages:146-153 extent:8 https://doi.org/10.1016/j.eururo.2012.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 65 2014 1 146-153 8 045F 610 |
| allfieldsGer |
10.1016/j.eururo.2012.05.007 doi GBVA2014010000014.pica (DE-627)ELV017491231 (ELSEVIER)S0302-2838(12)00541-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics Elsevier Segal, Scott oth Eastham, James oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:65 year:2014 number:1 pages:146-153 extent:8 https://doi.org/10.1016/j.eururo.2012.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 65 2014 1 146-153 8 045F 610 |
| allfieldsSound |
10.1016/j.eururo.2012.05.007 doi GBVA2014010000014.pica (DE-627)ELV017491231 (ELSEVIER)S0302-2838(12)00541-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics Elsevier Segal, Scott oth Eastham, James oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:65 year:2014 number:1 pages:146-153 extent:8 https://doi.org/10.1016/j.eururo.2012.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 65 2014 1 146-153 8 045F 610 |
| language |
English |
| source |
Enthalten in Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise Amsterdam [u.a.] volume:65 year:2014 number:1 pages:146-153 extent:8 |
| sourceStr |
Enthalten in Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise Amsterdam [u.a.] volume:65 year:2014 number:1 pages:146-153 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Thermodynamik statistische Physik Mathematik: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Castration-resistant prostate cancer Bone metastasis Prostate-specific antigen Skeletal complications Zoledronic acid Bisphosphonates PSA kinetics |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| authorswithroles_txt_mv |
Saad, Fred @@aut@@ Segal, Scott @@oth@@ Eastham, James @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000464341 |
| dewey-sort |
3610 |
| id |
ELV017491231 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017491231</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623135051.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eururo.2012.05.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014010000014.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017491231</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0302-2838(12)00541-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.25</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Saad, Fred</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Castration-resistant prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bone metastasis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate-specific antigen</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Skeletal complications</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Zoledronic acid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bisphosphonates</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSA kinetics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Segal, Scott</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eastham, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Feng, Jing ELSEVIER</subfield><subfield code="t">Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise</subfield><subfield code="d">2018</subfield><subfield code="d">official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000464341</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:65</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:146-153</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.eururo.2012.05.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.25</subfield><subfield code="j">Thermodynamik</subfield><subfield code="j">statistische Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.00</subfield><subfield code="j">Mathematik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">65</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">146-153</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Saad, Fred |
| spellingShingle |
Saad, Fred ddc 610 ddc 500 bkl 33.25 bkl 31.00 Elsevier Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid |
| authorStr |
Saad, Fred |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000464341 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 500 - Natural sciences & mathematics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics Elsevier |
| topic |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 Elsevier Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics |
| topic_unstemmed |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 Elsevier Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics |
| topic_browse |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 Elsevier Castration-resistant prostate cancer Elsevier Bone metastasis Elsevier Prostate-specific antigen Elsevier Skeletal complications Elsevier Zoledronic acid Elsevier Bisphosphonates Elsevier PSA kinetics |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s s ss j e je |
| hierarchy_parent_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| hierarchy_parent_id |
ELV000464341 |
| dewey-tens |
610 - Medicine & health 500 - Science |
| hierarchy_top_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000464341 |
| title |
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid |
| ctrlnum |
(DE-627)ELV017491231 (ELSEVIER)S0302-2838(12)00541-6 |
| title_full |
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid |
| author_sort |
Saad, Fred |
| journal |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| journalStr |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
146 |
| author_browse |
Saad, Fred |
| container_volume |
65 |
| physical |
8 |
| class |
610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Saad, Fred |
| doi_str_mv |
10.1016/j.eururo.2012.05.007 |
| dewey-full |
610 500 |
| title_sort |
prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid |
| title_auth |
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid |
| abstract |
Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. |
| abstractGer |
Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. |
| abstract_unstemmed |
Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| container_issue |
1 |
| title_short |
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid |
| url |
https://doi.org/10.1016/j.eururo.2012.05.007 |
| remote_bool |
true |
| author2 |
Segal, Scott Eastham, James |
| author2Str |
Segal, Scott Eastham, James |
| ppnlink |
ELV000464341 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.eururo.2012.05.007 |
| up_date |
2024-07-06T22:07:30.148Z |
| _version_ |
1803869120259686400 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017491231</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623135051.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eururo.2012.05.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014010000014.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017491231</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0302-2838(12)00541-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.25</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Saad, Fred</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Castration-resistant prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bone metastasis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate-specific antigen</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Skeletal complications</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Zoledronic acid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bisphosphonates</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PSA kinetics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Segal, Scott</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eastham, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Feng, Jing ELSEVIER</subfield><subfield code="t">Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise</subfield><subfield code="d">2018</subfield><subfield code="d">official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000464341</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:65</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:146-153</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.eururo.2012.05.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.25</subfield><subfield code="j">Thermodynamik</subfield><subfield code="j">statistische Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.00</subfield><subfield code="j">Mathematik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">65</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">146-153</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.402815 |